Results 31 to 40 of about 150,276 (218)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Neuroblastoma is the most common extracranial solid tumor in early childhood. Its clinical behavior is highly variable, ranging from spontaneous regression to fatal outcome despite intensive treatment. The International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) Radiology and Nuclear Medicine Specialty Committees ...
Annemieke Littooij +11 more
wiley +1 more source
Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background The United Kingdom relapsed Wilms tumour (UKW‐R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk‐stratified protocol. The trial also evaluated efficacy and toxicity of high‐dose melphalan.
Sucheta J. Vaidya +10 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen +23 more
wiley +1 more source
Heterogeneous Ensemble Model to Optimize Software Effort Estimation Accuracy
IEEE Access, 2023 The software industry has experienced rapid expansion in recent years, with software development now essential to the success of many multinational corporations.
Syed Sarmad Ali +4 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman +17 more
wiley +1 more source
Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors
Pediatric Blood &Cancer, EarlyView.ABSTRACT Introduction Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens.
Matthew T. McEvoy +5 more
wiley +1 more source
An Empirical Study on Software Test Effort Estimation for Defense Projects
IEEE Access, 2022 Effort estimation of software testing plays a vital role in the effective completion of testing. In particular, software test effort estimation in defense projects is not an easy and simple phenomenon, owing to internal and external factors.
Esra Cibir, Tulin Ercelebi Ayyildiz
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson +20 more
wiley +1 more source
Estimation of total Effort and Effort Elapsed in Each Step of Software Development Using Optimal Bayesian Belief Network [PDF]
Journal of Information Technology Management, 2017 Accuracy in estimating the needed effort for software development caused software effort estimation to be a challenging issue. Beside estimation of total effort, determining the effort elapsed in each software development step is very important because ...
Fatemeh Zare Baghiabad +3 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood. Methods We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332.
Jacquelyn N. Crane +11 more
wiley +1 more source